Dr. Rosenblatt is an advisor to PureTech Ventures. Dr. Rosenblatt has extensive experience in medicine, research, business administration and the pharmaceutical industry.
He is currently Chief Medical Officer and Executive Vice President and Head of Global Center for Scientific Affairs at Merck. He was the former the Dean of Tufts University School of Medicine, and served on the Shire Board of Directors.
Previously he was George R. Minot Professor of Medicine at Harvard Medical School and served as its Dean of Faculty.
From 1999 to 2001, Dr. Rosenblatt served as President of Beth Israel Deaconess. Their new state-of-the-art emergency department, cardiac catheterization, and intensive care units were envisioned, built and opened for service under his leadership. He also improved the financial performance of that institution and recruited in five new chiefs of service.
Previously, he served as Director of the Harvard-MIT Division of Health Sciences and Technology, a medical education organization for MD, PhD, and MD-PhD training jointly sponsored by Harvard and MIT.
Prior to that, he was Senior Vice President for Research at Merck Sharp & Dohme Research Laboratories where he headed the worldwide development team for alendronate (FOSAMAX), Merck's bisphosphonate for osteoporosis and bone disorders.
From 1981 to 1984, he served as Chief of the Endocrine Unit, Massachusetts General Hospital. He attended medical school at Harvard and completed his training at the Massachusetts General Hospital.